@misc{indiciae97eb90d386ba,
  title = {Pulsed priming with the FAK inhibitor narmafotinib enhances both gemcitabine/Abraxane and FOLFIRINOX chemotherapy response in pancreatic cancer},
  author = {Murphy, K. J. and Chambers, C. R. and Reed, D. A. and Channon, L. M. and Mills, N. E. and McKay, S. E. and Lee, V. and Howell, A. E. and Tran, A. M. and Nobis, M. and Magenau, A. and Stoehr, J. and Pereira, B. A. and Kuepper, N. and Ritchie, S. and Gordon, K. and Trpceski, M. and Tyma, V. M. and Hafiz, S. and Johri, V. and Ang, A. and Barkauskas, D. S. and Vennin, C. and Wang, X. Q. and Naeini, M. M. and Meyer, B. and Parker, A. L. and Gummadi, S. and Chitti, S. V. and Chacon Fajardo, D. and Zaratzian, A. and Tayao, M. and Da Silva, A. and Australian Pancreatic Genome Initiative (APGI), and Australian Pancreatic Matrix Atlas (APMA), and Cesare, A. J. and Mathivanan, S. and Stirzaker, C. and Latham, S.},
  year = {2026},
  doi = {10.64898/2026.07.23.740234},
  url = {https://www.biorxiv.org/content/10.64898/2026.07.23.740234v1},
  note = {Source identifier: 10.64898/2026.07.23.740234}
}